Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caffeine and AMPD1 polymorphism effects on LPS-induced inflammation in healthy volunteers
NL-OMON31085Phase 2Not yet recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Jul 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of caffeine and lipopolysaccharide endotoxin in septic shock and chronic inflammation (3 arms), sponsored by Radboud University Medical Center. Primary endpoints: Inflammatory response, Cytokines and adenosine concentrations and 2 more. Planned start Jul 2007; status: not yet recruiting.
02
Drugs
caffeinelipopolysaccharide endotoxin
03
Conditions
septic shockchronic inflammation
Beyond the preview
Go deeper on NL-OMON31085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31085.